AR018582A1 - Forma de dosificacion en tableta para administrar un antagonista de los receptores de los leucotrienos y su uso en la preparacion de medicamentos - Google Patents
Forma de dosificacion en tableta para administrar un antagonista de los receptores de los leucotrienos y su uso en la preparacion de medicamentosInfo
- Publication number
- AR018582A1 AR018582A1 ARP990100964A ARP990100964A AR018582A1 AR 018582 A1 AR018582 A1 AR 018582A1 AR P990100964 A ARP990100964 A AR P990100964A AR P990100964 A ARP990100964 A AR P990100964A AR 018582 A1 AR018582 A1 AR 018582A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- receptor antagonist
- leukotriene receptor
- antagonist
- receptors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una forma de dosificacion para administrar un antagonista de los receptores de leucotrienos utiles en la terapia antiasmática, a un paciente a lolargo del tiempo y el uso de una forma de dosificacion para preparar un medicamento para entregar losant agonistas. Una forma de dosificacion para entregar unantagonista de los receptores de los leucotrienos a un paciente que necesita una terapia basada en los mismos comprende: (a) una pared permeablea los fluidos e impermeable a un antagonista delos r eceptores de los leucotrienos; (b) una salida en la pared, para entregar el antagonista de losreceptores de los leucotrienos, desde la forma de dosificacion; y además comprende (c) una formulacion de droga que comprende un antagonista delosreceptore s de los leucotrienos y un vehículo farmacéuticamente aceptable para ayudar a la forma de dosificacion a entregar el antagonista de los receptoresde los leucotrienos desde la forma de dosificacion. Otra forma de dosificacion paraentregar un antagoni sta de los receptores de los leucotrienosa un entorno de utilizacion comprende: (a) una pared, que rodea un compartimiento; (b) una composicion de empuje, expandible en el compartimiento,en contacto con la formulacion de ladroga, que provee un empuj e continuo de modo de ayudar en la entrega del antagonista de los receptores de los leucotrienosdesde la forma de dosificacion; (c) una salida en la pared, para entregar el antagonista de los receptores de los leucotrienosdesde la forma dedosificaci on, y además comprende (d) la formulacion de una droga, que comprende un antagonista de los receptores de los leucotrienos y un vehículofarmacéuticamente aceptable para transportar el antagonista de los receptores de losleucotrienos desde la forma d e dosificacion. La forma de dosificacionen tableta comprende de 2 mg a 500 mg. de un antagonista de los receptores de los leucotrienos y de 20 mg a 300 mg de un vehículo carboxialquilcelulosa u oxido de polialquilenofarmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7709198P | 1998-03-06 | 1998-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018582A1 true AR018582A1 (es) | 2001-11-28 |
Family
ID=22136018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100964A AR018582A1 (es) | 1998-03-06 | 1999-03-05 | Forma de dosificacion en tableta para administrar un antagonista de los receptores de los leucotrienos y su uso en la preparacion de medicamentos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6224907B1 (es) |
| EP (1) | EP1059917B1 (es) |
| JP (1) | JP2002505275A (es) |
| AR (1) | AR018582A1 (es) |
| AT (1) | ATE292960T1 (es) |
| AU (1) | AU2882299A (es) |
| DE (1) | DE69924710T2 (es) |
| ES (1) | ES2237088T3 (es) |
| WO (1) | WO1999044592A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| WO2001021211A2 (en) * | 1999-09-20 | 2001-03-29 | Alza Corporation | Process for lessening polymorphic conversion of a drug |
| KR100381834B1 (ko) * | 2000-05-20 | 2003-04-26 | 이상득 | 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법 |
| AU2002303425A1 (en) * | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
| MY148466A (en) * | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| US20030175346A1 (en) * | 2002-02-01 | 2003-09-18 | Anne Billotte | Osmotic delivery system |
| US20030161882A1 (en) * | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
| US7226422B2 (en) | 2002-10-09 | 2007-06-05 | Cardiac Pacemakers, Inc. | Detection of congestion from monitoring patient response to a recumbent position |
| US7148248B2 (en) * | 2002-11-29 | 2006-12-12 | Masako Nozaki | Method of treating or inhibiting the development of brain inflammation and sepsis |
| US20090317476A1 (en) * | 2003-07-31 | 2009-12-24 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026882A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| WO2005040123A1 (en) * | 2003-10-10 | 2005-05-06 | Synhton B. V. | Solid-state montelukast |
| AU2005210236B2 (en) * | 2004-02-03 | 2010-09-09 | Chemagis Ltd. | Stable amorphous forms of montelukast sodium |
| US7387610B2 (en) | 2004-08-19 | 2008-06-17 | Cardiac Pacemakers, Inc. | Thoracic impedance detection with blood resistivity compensation |
| WO2006066780A1 (en) * | 2004-12-22 | 2006-06-29 | F. Hoffmann-La Roche Ag | Combinations of valategrast and montelukast for treating asthma |
| US20080254114A1 (en) * | 2005-03-03 | 2008-10-16 | Elan Corporation Plc | Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles |
| WO2006099591A1 (en) * | 2005-03-16 | 2006-09-21 | Elan Pharma International Limited | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
| US7603170B2 (en) * | 2005-04-26 | 2009-10-13 | Cardiac Pacemakers, Inc. | Calibration of impedance monitoring of respiratory volumes using thoracic D.C. impedance |
| US7907997B2 (en) * | 2005-05-11 | 2011-03-15 | Cardiac Pacemakers, Inc. | Enhancements to the detection of pulmonary edema when using transthoracic impedance |
| US9089275B2 (en) * | 2005-05-11 | 2015-07-28 | Cardiac Pacemakers, Inc. | Sensitivity and specificity of pulmonary edema detection when using transthoracic impedance |
| JP4870402B2 (ja) * | 2005-09-01 | 2012-02-08 | 小林化工株式会社 | プランルカスト水和物含有錠の製造方法 |
| US20070110802A1 (en) * | 2005-11-15 | 2007-05-17 | Janan Jona | Wet granulation process |
| WO2007059325A2 (en) * | 2005-11-16 | 2007-05-24 | Teva Pharmaceutical Industries Ltd. | Drying methods of montelukast sodium by azeotropic removal of the solvent |
| WO2007092031A1 (en) * | 2006-02-09 | 2007-08-16 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of montelukast sodium |
| US20090012146A1 (en) * | 2007-07-02 | 2009-01-08 | Giridhar Reddy Buggana | Solubility-enhanced pharmaceutical compositions comprising zafirlukast |
| US8093253B2 (en) * | 2008-03-06 | 2012-01-10 | Hoffmann-La Roche Inc. | Leukotriene B4 inhibitors |
| CN101543480A (zh) * | 2008-03-28 | 2009-09-30 | 兴和株式会社 | 片剂 |
| JP2013540464A (ja) | 2010-08-30 | 2013-11-07 | サイナシス コーポレーション | 副鼻腔開口部を拡張するため、および副鼻腔炎を治療するためのデバイスおよび方法 |
| JP2015509786A (ja) | 2012-02-29 | 2015-04-02 | サイナシス コーポレーション | 副鼻腔開口部を拡張して副鼻腔炎を治療するためのデバイスおよび方法 |
| US9687263B2 (en) | 2013-05-30 | 2017-06-27 | SinuSys Corporation | Devices and methods for inserting a sinus dilator |
| PT109030B (pt) * | 2015-12-15 | 2019-09-25 | Hovione Farmaciência, S.A. | Preparação de partículas inaláveis de zafirlucaste |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
| US5208037A (en) * | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
| WO1993017709A1 (fr) | 1992-03-12 | 1993-09-16 | Ono Pharmaceutical Co., Ltd. | Agent antiprurigineux |
| DK0621032T3 (da) * | 1993-04-23 | 2000-10-23 | Novartis Ag | Lægemiddelform med reguleret afgivelse |
| EP0697868A4 (en) * | 1993-05-10 | 1998-04-08 | Sepracor Inc | THERAPIES AND COMPOSITIONS USING OPTICALLY PURE (+) - ZILEUTON |
| US5529787A (en) * | 1994-07-07 | 1996-06-25 | Alza Corporation | Hydromorphone therapy |
| EP0844870B1 (en) | 1995-08-17 | 2001-11-21 | Csir | Controlled release products |
-
1999
- 1999-02-12 US US09/250,288 patent/US6224907B1/en not_active Expired - Lifetime
- 1999-02-26 JP JP2000534194A patent/JP2002505275A/ja active Pending
- 1999-02-26 ES ES99909667T patent/ES2237088T3/es not_active Expired - Lifetime
- 1999-02-26 AT AT99909667T patent/ATE292960T1/de not_active IP Right Cessation
- 1999-02-26 WO PCT/US1999/004350 patent/WO1999044592A1/en not_active Ceased
- 1999-02-26 AU AU28822/99A patent/AU2882299A/en not_active Abandoned
- 1999-02-26 EP EP99909667A patent/EP1059917B1/en not_active Expired - Lifetime
- 1999-02-26 DE DE69924710T patent/DE69924710T2/de not_active Expired - Fee Related
- 1999-03-05 AR ARP990100964A patent/AR018582A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1059917B1 (en) | 2005-04-13 |
| DE69924710D1 (de) | 2005-05-19 |
| US6224907B1 (en) | 2001-05-01 |
| AU2882299A (en) | 1999-09-20 |
| ES2237088T3 (es) | 2005-07-16 |
| WO1999044592A1 (en) | 1999-09-10 |
| JP2002505275A (ja) | 2002-02-19 |
| HK1033278A1 (en) | 2001-08-24 |
| DE69924710T2 (de) | 2005-09-15 |
| ATE292960T1 (de) | 2005-04-15 |
| EP1059917A1 (en) | 2000-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018582A1 (es) | Forma de dosificacion en tableta para administrar un antagonista de los receptores de los leucotrienos y su uso en la preparacion de medicamentos | |
| CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
| AR005281A1 (es) | Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. . | |
| IT1201136B (it) | Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive | |
| YU33099A (sh) | Farmaceutska smesa za poboljšanje erektilne disfunkcije kod muškaraca | |
| AR017979A1 (es) | Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento | |
| AU4989997A (en) | Soluble form osmotic dose delivery system | |
| AR066313A2 (es) | Una formulacion de liberacion controlada de galantamina, una forma farmaceutica de dosificacion, un proceso para la preparacion de dicha formulacion, y el uso de dicha formulacion para la manufactura de un medicamento | |
| AR014467A1 (es) | Unidad de dosis farmaceutica oralmente administrable de un tamano superior a 7 mm que comprende una droga y un recubrimiento externo, un metodo paraseparar una unidad de dosis farmaceutica oralmente administrable a partir de un alimento co-administrado y el uso de una droga y un material de recubrim | |
| CO5261582A1 (es) | Composiciones de valdecoxib | |
| RU2005102105A (ru) | Способы и лекарственные формы для контролируемой доставки палиперидона | |
| WO2004054542A3 (en) | Oral drug delivery system comprising high viscosity liquid carrier materials | |
| RU97115570A (ru) | Применение неорганических аэрогелей в фармации | |
| ES2075444T3 (es) | Sistema de dosificado osmotico para la administracion de un farmaco liquido. | |
| AR002009A1 (es) | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. | |
| BR0007974A (pt) | Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo | |
| EP0822809A4 (en) | SLOW RELEASE FORMULATION OF WATER SOLUBLE DRUGS WITH INCORPORATED PASSAGE | |
| ES2196382T3 (es) | Administracion y envase de medicamentos. | |
| ES2157975T3 (es) | Soluciones farmaceuticas con solubilidad mejorada. | |
| EA200101026A1 (ru) | Предварительно желатинированный крахмал в композиции с контролируемым высвобождением | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| CO5690530A2 (es) | Sistema de suministro de farmacos | |
| Frick et al. | Drug-induced acute pancreatitis: further criticism | |
| CL2009001899A1 (es) | Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01). | |
| ATE292453T1 (de) | Antivirale arznei |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |